In the adenocarcinoma group not receiving PD-1/PD-L1 inhibitor treatment, the immunohistochemical expression of YTHDF1 or YTHDF2 was correlated with better overall survival (p = 0.023, Figure 4A and p = 0.023, Figure 4C, respectively). This evidence concerns the gene PDCD1 and adenocarcinoma.